$FRO

Why is Frontline stock sliding today?

Frontline (FRO) stock is down 6.0% in pre-market trading as it goes ex-dividend, with a total payout of $3.41 per share. The dividend includes a regular Q2 2026 payment of $2.61 and a special dividend of $0.80, funded by vessel sales. The company reported a net income of $659 million in Q2 2026. Analysts have mixed sentiments, with BTIG maintaining a Buy rating.

Original reporting
Published Sep 18, 2026, 9:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$FRO
Neutral
high confidence
Mentioned
$FRO
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FRONeutralLow
01

Why it matters

The ex‑dividend price adjustment explains the 6% pre‑market slide, aligning with typical market mechanics for dividend payouts.

02

Market read

The news is a routine corporate action that primarily affects Frontline's share price in the short term; broader market impact is limited.

03

What to watch

The special dividend funded by VLCC sales could indicate asset liquidation trends that may affect future earnings.

Relevance 5/10Novelty 5/10Timing: pre‑market today

Background

Frontline Ltd announced a regular Q2 2026 dividend of $2.61 per share and a special $0.80 dividend funded by vessel sales, with an ex‑dividend date of September 18, 2026.

Company-level read

Ticker impact

$FRONeutralHigh confidence
Context

Frontline shares slid 6% in pre‑market as the stock went ex‑dividend for a $3.41 combined regular and special dividend.

Expected impact

Expect the stock to trade near the post‑dividend level of about $50‑51 after the market opens.

Evidence & confidence

The dividend amount is known and the price move is a textbook mechanical effect; no new fundamental change is implied.

Market effects

The dividend payout signals strong cash flow for the tanker sector, but has limited impact on peers beyond standard ex‑dividend adjustments.

Minimal; the move is confined to Frontline and does not affect broader market indices.

Low; the event is a routine corporate action with no macro‑economic significance.

Counterpoint

Short sellers might view the ex‑dividend drop as a buying opportunity if they believe the dividend reflects sustainable earnings.

Key entities

  • Frontline Ltd

    Global tanker operator listed on NYSE under ticker FRO.

Related articles

$PFEHighAI 9/10

FDA Approves Pfizer's TUKYSA for Frontline HER2-Positive Breast

Pfizer (PFE) announced FDA approval of TUKYSA for HER2-positive breast cancer, expanding its use as a maintenance therapy. The company has a 6.11% dividend yield, a 71% payout ratio, and trades near its GF Value of $26.42. Pfizer's GF Score is 74, reflecting strengths in profitability and valuation but moderate growth. Insiders have shown net buying, and 23 guru investors hold shares.

$ABBVHighAI 9/10

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

$FROMed

Nordic tanker stocks climb on record-high shipping rates

Nordic-listed tanker companies' shares rose Monday due to record-high shipping rates. Frontline (FRO) gained 6%, while Hafnia (HAFNI), Capital Tankers (CAPT), and TORM (TRMD) increased 4-6%. Suezmax rates jumped 70% week-on-week, impacting companies' revenue and outlook, according to Danske Bank analyst Bendik Folden Nyttingnes.

$RVMDHighAI 8/10

RVMD: Pancreatic Cancer Approval And Frontline RAS Expansion Still Drive Upside

Revolution Medicines' fair value estimate increased to $257.47, up $6, due to pipeline progress and product approvals. Analysts highlight potential from drugs like daraxonrasib and zoldonrasib, while noting competition and execution risks. The FDA approved Rasonque for pancreatic cancer, with a $39,800/month price, and granted Breakthrough Therapy Designation for its combination therapy. Revenue growth assumptions rose to 1,439.45%.